952958-66-6 Usage
Uses
Used in Pharmaceutical Industry:
CCPA is utilized as a key building block for the synthesis of various drugs, particularly in the development of new pharmaceutical compounds. Its unique properties and reactivity make it an important intermediate in drug discovery and development processes.
Used in Drug Synthesis:
As a crucial component in the production of a wide range of pharmaceuticals, CCPA is employed as an intermediate in the synthesis of drugs with diverse therapeutic applications, contributing to the advancement of medical treatments and healthcare solutions.
Check Digit Verification of cas no
The CAS Registry Mumber 952958-66-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,5,2,9,5 and 8 respectively; the second part has 2 digits, 6 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 952958-66:
(8*9)+(7*5)+(6*2)+(5*9)+(4*5)+(3*8)+(2*6)+(1*6)=226
226 % 10 = 6
So 952958-66-6 is a valid CAS Registry Number.
952958-66-6Relevant academic research and scientific papers
Amide compound and application thereof as TGR5 agonist
-
, (2017/04/20)
Belonging to the technical field of medicine, the invention in particular relates to an amide TGR5 agonist compound shown as formula (I), its pharmaceutically acceptable salts, esters, stereoisomers, solvent compounds or prodrugs, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, X, Y, Z, and ring A are defined as the specification. The invention also relates to a preparation method of the compounds, pharmaceutical preparations, pharmaceutical compositions, and application of the compounds in preparation of drugs for treatment and/or prevention of TGR5 activity regulation related diseases. (formula (I)).
HETEROCYCLIC MODULATORS OF GPR119 FOR TREATMENT OF DISEASE
-
Page/Page column 113, (2009/10/22)
The present invention relates to compounds and methods which may be useful as inhibitors of GPR119 for the treatment or prevention of metabolic, cardiovascular, and metabolic diseases.
